BMS-212122 | CAS#194213-64-4 |MTP inhibitor

MedKoo Cat#: 524453 | Name: BMS-212122

Description:

WARNING: This product is for research use only, not for human or veterinary use.

BMS-212122 is a potent microsomal triglyceride transfer protein inhibitor (MTP inhibitor). MS-212122 is significantly more potent than BMS-201038 in reducing plasma lipids (cholesterol, VLDL/LDL, TG) in both hamsters and cynomolgus monkeys. Treatment with BMS-212122 led to rapid reduction in plasma lipid levels, which were accompanied by a significant decrease in lipid content and monocyte-derived (CD68+) cells in atherosclerotic plaques compared to baseline and chow diet control groups. BMS-212122-treated mice had increased collagen content, a marker associated with increased stability in human plaques.

Chemical Structure

BMS-212122

CAS#194213-64-4

Theoretical Analysis

MedKoo Cat#: 524453

Name: BMS-212122

CAS#: 194213-64-4

Chemical Formula: C43H36F6N4O2

Exact Mass: 754.2743

Molecular Weight: 754.76

Elemental Analysis: C, 68.43; H, 4.81; F, 15.10; N, 7.42; O, 4.24

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

BMS-212122; BMS212122; BMS 212122; UNII-0Z473OO6GB.

IUPAC/Chemical Name

9-(4-(2,5-dimethyl-4-(4'-(trifluoromethyl)-[1,1'-biphenyl]-2-carboxamido)-1H-benzo[d]imidazol-1-yl)butyl)-N-(2,2,2-trifluoroethyl)-9H-fluorene-9-carboxamide

InChi Key

PCOWNQCLFYEXLR-UHFFFAOYSA-N

InChi Code

InChI=1S/C43H36F6N4O2/c1-26-17-22-36-38(37(26)52-39(54)33-14-4-3-11-30(33)28-18-20-29(21-19-28)43(47,48)49)51-27(2)53(36)24-10-9-23-41(40(55)50-25-42(44,45)46)34-15-7-5-12-31(34)32-13-6-8-16-35(32)41/h3-8,11-22H,9-10,23-25H2,1-2H3,(H,50,55)(H,52,54)

SMILES Code

O=C(C1(CCCCN2C3=CC=C(C)C(NC(C4=CC=CC=C4C5=CC=C(C(F)(F)F)C=C5)=O)=C3N=C2C)C6=C(C7=C1C=CC=C7)C=CC=C6)NCC(F)(F)F

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO, not in water

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 754.76 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Hewing B, Parathath S, Mai CK, Fiel MI, Guo L, Fisher EA. Rapid regression of atherosclerosis with MTP inhibitor treatment. Atherosclerosis. 2013 Mar;227(1):125-9. doi: 10.1016/j.atherosclerosis.2012.12.026. PubMed PMID: 23332773; PubMed Central PMCID: PMC4047651. 2: Robl JA, Sulsky R, Sun CQ, Simpkins LM, Wang T, Dickson JK Jr, Chen Y, Magnin DR, Taunk P, Slusarchyk WA, Biller SA, Lan SJ, Connolly F, Kunselman LK, Sabrah T, Jamil H, Gordon D, Harrity TW, Wetterau JR. A novel series of highly potent benzimidazole-based microsomal triglyceride transfer protein inhibitors. J Med Chem. 2001 Mar 15;44(6):851-6. PubMed PMID: 11300866. 3: Dikkers A, Annema W, de Boer JF, Iqbal J, Hussain MM, Tietge UJ. Differential impact of hepatic deficiency and total body inhibition of MTP on cholesterol metabolism and RCT in mice. J Lipid Res. 2014 May;55(5):816-25. doi: 10.1194/jlr.M042986. PubMed PMID: 24511105; PubMed Central PMCID: PMC3995460.